Cantor Fitzgerald reaffirmed their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research note released on Tuesday morning. Cantor Fitzgerald currently has a $162.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Robert W. Baird restated a buy rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Thursday, September 21st. Jefferies Group LLC restated a buy rating and set a $160.00 price objective on shares of Celgene Corporation in a research note on Friday, September 15th. Mizuho lifted their price objective on shares of Celgene Corporation from $134.00 to $158.00 and gave the company a buy rating in a research note on Friday, September 15th. Royal Bank Of Canada began coverage on shares of Celgene Corporation in a research note on Thursday, September 14th. They set a top pick rating and a $176.00 price objective for the company. Finally, Bank of America Corporation restated a buy rating on shares of Celgene Corporation in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $150.31.

Shares of Celgene Corporation (NASDAQ CELG) traded up 2.14% during mid-day trading on Tuesday, hitting $145.82. 4,324,637 shares of the stock were exchanged. The stock’s 50-day moving average price is $135.45 and its 200-day moving average price is $127.81. The company has a market cap of $114.08 billion, a P/E ratio of 45.16 and a beta of 1.89. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $146.00.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the business posted $1.44 EPS. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/30/cantor-fitzgerald-reiterates-buy-rating-for-celgene-corporation-celg.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 in the last ninety days. 0.95% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of CELG. Janus Henderson Group PLC lifted its position in Celgene Corporation by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after buying an additional 8,217,433 shares during the last quarter. BlackRock Inc. lifted its position in Celgene Corporation by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Oaktop Capital Management II L.P. acquired a new position in Celgene Corporation in the second quarter valued at about $271,605,000. Arrowstreet Capital Limited Partnership lifted its position in Celgene Corporation by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after buying an additional 1,787,052 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Celgene Corporation by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. 79.33% of the stock is currently owned by institutional investors.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.